{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:25:17Z","timestamp":1762017917610},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Medicine Ramathibodi Hospital","award":["IO-R1 1058032"],"award-info":[{"award-number":["IO-R1 1058032"]}]},{"name":"Kowa Company Limited (Japan)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0157531","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T19:21:10Z","timestamp":1466018470000},"page":"e0157531","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir\/Ritonavir: A Randomized, Double-Blind, Crossover Study"],"prefix":"10.1371","volume":"11","author":[{"given":"Asita","family":"Wongprikorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawin","family":"Numthavej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,6,15]]},"reference":[{"key":"ref1","first-page":"49","article-title":"Dyslipidemia related to antiretroviral therapy","volume":"13","author":"V Estrada","year":"2011","journal-title":"AIDS Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2005.09.025","article-title":"Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis","volume":"185","author":"SD Fisher","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1373\/clinchem.2006.069583","article-title":"Protease inhibitor-associated dyslipidemia in HIV- infected patients is strongly influenced by the APOA5-1131T->C gene variation","volume":"52","author":"M Guardiola","year":"2006","journal-title":"Clin Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e1000305","DOI":"10.1371\/journal.pcbi.1000305","article-title":"Timing the emergence of resistance to anti-HIV drugs with large genetic barriers","volume":"5","author":"P Arora","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidemia in Human Immunodeficiency Virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group","volume":"37","author":"PM Dube","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV","volume":"9","author":"JD Luwdgren","year":"2008","journal-title":"HIV Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia","volume":"19","author":"L Calza","year":"2005","journal-title":"AIDS"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs mechanisms and clinical relevance","volume":"80","author":"DJ Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","unstructured":"Livalo [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.\/Indianapolis, IN: Eli Lilly and Company. 2012."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/0049825021000017957","article-title":"Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization","volume":"33","author":"H Fujino","year":"2003","journal-title":"Xenobiotica"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacl.2013.03.051","article-title":"Pitavastatin 4 mg provides superior LDL-C reduction vs pravastatin 40 mg over 12 weeks in HIV-infected adults with dyslipidemia, the INTREPID trial","volume":"7","author":"CA Sponseller","year":"2013","journal-title":"J Clin Lipidol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/INF.0000000000000469","article-title":"Pharmacokinetics of atazanavir\/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate","volume":"33","author":"T Bunupuradah","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.metabol.2005.08.018","article-title":"Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy","volume":"55","author":"SB Haugaard","year":"2006","journal-title":"Metabolism"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/VHRM.S7802","article-title":"Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia","volume":"6","author":"J Sasaki","year":"2010","journal-title":"Vas Health Risk Manag"},{"issue":"23 Suppl 1","key":"ref16","first-page":"50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"S Bellosta","year":"2004","journal-title":"Circulation"},{"key":"ref17","first-page":"971","article-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"RW Mahley","year":"2001"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-COA reductase inhibitors","volume":"23","author":"JA Farmer","year":"2000","journal-title":"Drug Saf"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/0002-9149(88)90004-5","article-title":"Efficacy and long-term adverse effect pattern of lovastatin","volume":"62","author":"JA Tobert","year":"1988","journal-title":"Am J Cardiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dki235","article-title":"Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy","volume":"56","author":"A Winston","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bjid.2013.04.002","article-title":"Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load","volume":"17","author":"AJ Luz","year":"2013","journal-title":"Braz J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0157531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T19:55:57Z","timestamp":1568058957000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0157531"}},"subtitle":[],"editor":[{"given":"Javier R.","family":"Lama","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,15]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0157531","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,15]]}}}